Radionuclides for radioimmunotherapy: criteria for selection

Area of Science:

• Nuclear medicine
• Radiopharmaceutical therapy
• Medical physics

Background:

• Isotope selection is a critical factor in radioimmunotherapy (RIT) design.
• Key considerations include radiological performance, pharmacodynamics, and logistical feasibility.
• Understanding the distinct effects of alpha and beta particles is essential for optimizing treatment.

Purpose of the Study:

• To evaluate the criteria and parameters influencing isotope selection in RIT.
• To compare the properties of various alpha-emitting isotopes for RIT applications.
• To identify promising isotope combinations for future RIT development.

Main Methods:

• Review of radiological and pharmacodynamic properties of RIT isotopes.
• Assessment of feasibility factors including availability, handling, and patient safety.
• Comparative analysis of alpha-emitting isotopes based on established criteria.

Main Results:

• Isotope selection impacts RIT usefulness and feasibility through radiological and pharmacodynamic performance.
• Alpha particles offer distinct therapeutic advantages over beta particles.
• The combination of Actinium-225 (225Ac) and Bismuth-213 (213Bi) demonstrates favorable characteristics.

Conclusions:

• The 225Ac-213Bi isotope combination warrants further in-depth investigation for radioimmunotherapy.
• Optimized isotope selection enhances therapeutic efficacy and patient safety in RIT.
• Continued research into alpha-emitters can advance the field of targeted cancer therapy.